Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black
{"title":"特发性嗜睡和发作性睡的临床和经济负担：一项基于美国索赔的分析。","authors":"Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black","doi":"10.2147/NSS.S498213","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Idiopathic hypersomnia and narcolepsy are similar but distinct sleep disorders. This study evaluated the clinical and economic burden experienced by individuals with either condition.</p><p><strong>Patients and methods: </strong>Merative<sup>™</sup> MarketScan<sup>®</sup> Research Databases claims were analyzed (study period, 12/31/2013-2/29/2020). Eligible individuals were ≥18 years of age, continuously enrolled (365 days before/after cohort entry), and had a claim for either condition. Those with cataplexy were excluded from the idiopathic hypersomnia cohort. Individuals entered cohorts upon their earliest claim for their condition during the study period. Clinical classification categories, select conditions, healthcare resource utilization (HCRU), and medical costs were assessed over a 2-year period. Percentages of individuals with comorbid conditions were summarized. Mean (SD) HCRU and total all-cause medical costs were presented per patient per year (PPPY). HCRU and medical costs PPPY were HCRU or medical costs 365 days before/after cohort entry divided by 2.</p><p><strong>Results: </strong>11,426 individuals with idiopathic hypersomnia and 31,214 with narcolepsy were included. Median ages were 45 and 43 years, respectively; approximately 65% of each cohort was female. Mean numbers of comorbid conditions across all categories were 15.4 (5.4) and 14.6 (5.7), respectively. Ill-defined conditions (95.6%, 94.4%), nervous system diseases (83.8%, 100.0%), and respiratory system diseases (83.6%, 79.1%) were most common broad clinical classification categories. Both cohorts experienced sleep apnea (62.8%, 52.1%), hypertension (45.7%, 42.9%), hyperlipidemia (42.2%, 38.4%), pain (66.4%, 66.0%), and mood disorders (41.9%, 43.3%). Mean all-cause outpatient visits PPPY among those with ≥1 visit were 28.2 (40.1) and 27.4 (40.6) for individuals with idiopathic hypersomnia or narcolepsy, respectively. Mean all-cause medical costs PPPY were $11,134 ($22,674) and $11,591 ($25,956) for individuals with idiopathic hypersomnia or narcolepsy.</p><p><strong>Conclusion: </strong>Individuals with narcolepsy and idiopathic hypersomnia experience comorbid conditions which bear consequences for healthcare systems; these may be considered when evaluating overall health of individuals with either condition.</p>","PeriodicalId":18896,"journal":{"name":"Nature and Science of Sleep","volume":"17 ","pages":"1809-1823"},"PeriodicalIF":3.4000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341555/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Clinical and Economic Burden of Idiopathic Hypersomnia and Narcolepsy: A United States Claims-Based Analysis.\",\"authors\":\"Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black\",\"doi\":\"10.2147/NSS.S498213\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Idiopathic hypersomnia and narcolepsy are similar but distinct sleep disorders. This study evaluated the clinical and economic burden experienced by individuals with either condition.</p><p><strong>Patients and methods: </strong>Merative<sup>™</sup> MarketScan<sup>®</sup> Research Databases claims were analyzed (study period, 12/31/2013-2/29/2020). Eligible individuals were ≥18 years of age, continuously enrolled (365 days before/after cohort entry), and had a claim for either condition. Those with cataplexy were excluded from the idiopathic hypersomnia cohort. Individuals entered cohorts upon their earliest claim for their condition during the study period. Clinical classification categories, select conditions, healthcare resource utilization (HCRU), and medical costs were assessed over a 2-year period. Percentages of individuals with comorbid conditions were summarized. Mean (SD) HCRU and total all-cause medical costs were presented per patient per year (PPPY). HCRU and medical costs PPPY were HCRU or medical costs 365 days before/after cohort entry divided by 2.</p><p><strong>Results: </strong>11,426 individuals with idiopathic hypersomnia and 31,214 with narcolepsy were included. Median ages were 45 and 43 years, respectively; approximately 65% of each cohort was female. Mean numbers of comorbid conditions across all categories were 15.4 (5.4) and 14.6 (5.7), respectively. Ill-defined conditions (95.6%, 94.4%), nervous system diseases (83.8%, 100.0%), and respiratory system diseases (83.6%, 79.1%) were most common broad clinical classification categories. Both cohorts experienced sleep apnea (62.8%, 52.1%), hypertension (45.7%, 42.9%), hyperlipidemia (42.2%, 38.4%), pain (66.4%, 66.0%), and mood disorders (41.9%, 43.3%). Mean all-cause outpatient visits PPPY among those with ≥1 visit were 28.2 (40.1) and 27.4 (40.6) for individuals with idiopathic hypersomnia or narcolepsy, respectively. Mean all-cause medical costs PPPY were $11,134 ($22,674) and $11,591 ($25,956) for individuals with idiopathic hypersomnia or narcolepsy.</p><p><strong>Conclusion: </strong>Individuals with narcolepsy and idiopathic hypersomnia experience comorbid conditions which bear consequences for healthcare systems; these may be considered when evaluating overall health of individuals with either condition.</p>\",\"PeriodicalId\":18896,\"journal\":{\"name\":\"Nature and Science of Sleep\",\"volume\":\"17 \",\"pages\":\"1809-1823\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341555/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature and Science of Sleep\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/NSS.S498213\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature and Science of Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/NSS.S498213","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
The Clinical and Economic Burden of Idiopathic Hypersomnia and Narcolepsy: A United States Claims-Based Analysis.
Purpose: Idiopathic hypersomnia and narcolepsy are similar but distinct sleep disorders. This study evaluated the clinical and economic burden experienced by individuals with either condition.
Patients and methods: Merative™ MarketScan® Research Databases claims were analyzed (study period, 12/31/2013-2/29/2020). Eligible individuals were ≥18 years of age, continuously enrolled (365 days before/after cohort entry), and had a claim for either condition. Those with cataplexy were excluded from the idiopathic hypersomnia cohort. Individuals entered cohorts upon their earliest claim for their condition during the study period. Clinical classification categories, select conditions, healthcare resource utilization (HCRU), and medical costs were assessed over a 2-year period. Percentages of individuals with comorbid conditions were summarized. Mean (SD) HCRU and total all-cause medical costs were presented per patient per year (PPPY). HCRU and medical costs PPPY were HCRU or medical costs 365 days before/after cohort entry divided by 2.
Results: 11,426 individuals with idiopathic hypersomnia and 31,214 with narcolepsy were included. Median ages were 45 and 43 years, respectively; approximately 65% of each cohort was female. Mean numbers of comorbid conditions across all categories were 15.4 (5.4) and 14.6 (5.7), respectively. Ill-defined conditions (95.6%, 94.4%), nervous system diseases (83.8%, 100.0%), and respiratory system diseases (83.6%, 79.1%) were most common broad clinical classification categories. Both cohorts experienced sleep apnea (62.8%, 52.1%), hypertension (45.7%, 42.9%), hyperlipidemia (42.2%, 38.4%), pain (66.4%, 66.0%), and mood disorders (41.9%, 43.3%). Mean all-cause outpatient visits PPPY among those with ≥1 visit were 28.2 (40.1) and 27.4 (40.6) for individuals with idiopathic hypersomnia or narcolepsy, respectively. Mean all-cause medical costs PPPY were $11,134 ($22,674) and $11,591 ($25,956) for individuals with idiopathic hypersomnia or narcolepsy.
Conclusion: Individuals with narcolepsy and idiopathic hypersomnia experience comorbid conditions which bear consequences for healthcare systems; these may be considered when evaluating overall health of individuals with either condition.
期刊介绍：
Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep.
Specific topics covered in the journal include:
The functions of sleep in humans and other animals
Physiological and neurophysiological changes with sleep
The genetics of sleep and sleep differences
The neurotransmitters, receptors and pathways involved in controlling both sleep and wakefulness
Behavioral and pharmacological interventions aimed at improving sleep, and improving wakefulness
Sleep changes with development and with age
Sleep and reproduction (e.g., changes across the menstrual cycle, with pregnancy and menopause)
The science and nature of dreams
Sleep disorders
Impact of sleep and sleep disorders on health, daytime function and quality of life
Sleep problems secondary to clinical disorders
Interaction of society with sleep (e.g., consequences of shift work, occupational health, public health)
The microbiome and sleep
Chronotherapy
Impact of circadian rhythms on sleep, physiology, cognition and health
Mechanisms controlling circadian rhythms, centrally and peripherally
Impact of circadian rhythm disruptions (including night shift work, jet lag and social jet lag) on sleep, physiology, cognition and health
Behavioral and pharmacological interventions aimed at reducing adverse effects of circadian-related sleep disruption
Assessment of technologies and biomarkers for measuring sleep and/or circadian rhythms
Epigenetic markers of sleep or circadian disruption.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
